Macrophage mitochodrial reprogramming and innate immune memory
Macrophage mitochodrial reprogramming and innate immune memory
批准号:
10333362
负责人:
EDWARD R SHERWOOD
金额:
$42.5万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-02-13 至 2025-01-31
关键词:
Aconitic AcidAdaptive Immune SystemAffectAgonistAmericanAntimicrobial EffectAutomobile DrivingBiogenesisBiologyBurn TraumaCause of DeathCell RespirationCell physiologyCellsCessation of lifeCitric AcidCitric Acid CycleClinicalComplicationCritical IllnessDevelopmentFRAP1 geneFoundationsGenesGlycolysisGoalsHealthcare SystemsHospitalsImmuneImmune responseImmunologic MemoryImmunotherapyIncidenceIndividualInfectionInnate Immune ResponseInnate Immune SystemKnockout MiceKnowledgeLeukocytesLigandsLipid AMemoryMetabolicMetabolismMitochondriaModelingMolecularMyeloid CellsNosocomial InfectionsOrganismOxidative PhosphorylationPathway interactionsPatientsPeptidoglycanPhenotypePlayProductionPseudomonas aeruginosaPublic HealthResistanceResistance to infectionRoleSepsisSeveritiesSignal PathwaySignal TransductionStaphylococcus aureus infectionTLR4 geneTestingVaccinesVulnerable Populationsantimicrobialbasebeta-Glucansclinically relevantcognitive disabilitycytokinegene producthigh riskimmune resistanceimmune system functionin vivomacrophagemetabolic phenotypemicrobialmitochondrial metabolismmortalityorgan injurypathogenpathogen exposurepathogenic bacteriapathogenic fungusphysically handicappedpreventrecruitresponsesevere burnssurgical risk
中文摘要
项目摘要
医院获得性感染是对公共卫生的主要威胁,影响200万患者,
每年至少有9万人死亡。脓毒症是医院感染患者常见的并发症
也是非心脏重症监护病房(ICU)的主要死亡原因。尝试治疗医院获得性
感染和脓毒症已被证明是极其困难的,
身体和认知残疾以及高1年死亡率。因此,需要新的战略,
减少医院获得性感染和败血症的负担。免疫治疗旨在诱导
先天免疫记忆提供了一种实现这一目标的方法。最近的研究表明,先天免疫
细胞可以保留先前的病原体暴露的记忆,并引发一个强大的,广谱的,
对后续感染的抗菌反应。用TLR 4配体如单磷酰脂质A治疗
(MPLA),赋予先天免疫记忆和对广泛的临床上重要的病原体的抗性,
持续2周以上。我们建议适当应用基于TLR 4配体的
诱导先天免疫记忆的免疫疗法具有显著的潜力,
医院获得性感染和败血症。宏观调控是先天性发育的基础
免疫记忆最近的证据表明,巨噬细胞代谢的重塑是细胞凋亡的核心。
诱导先天免疫记忆。用TLR 4配体引发诱导巨噬细胞代谢表型
其特征在于糖酵解、氧化代谢和线粒体生物合成增加,
酸循环通量和免疫应答基因1(Irg 1)表达和衣康酸相关增加
生产我们假设巨噬细胞代谢重塑和增加的
irg 1和衣康酸是产生先天免疫记忆所必需的。为了定义潜在的生物学,
我们会:(1)。确定Irg 1和衣康酸盐如何驱动TLR 4激动剂诱导的先天免疫记忆,
巨噬细胞;(2)。确定Irg 1、衣康酸和Nrf 2作为宿主对以下疾病反应的调节剂的重要性:
体内TLR 4激动剂治疗后常见的医院获得性病原体感染。(三)、定义
细胞内信号通路驱动线粒体生物发生,Irg 1表达和衣康酸生产,
TLR 4激动剂引发的巨噬细胞;(4).确定不同微生物配体诱导
巨噬细胞线粒体生物合成,重新编程线粒体代谢和功能,并诱导先天性
免疫记忆我们将检验这样的假设,即像TLR 4激动剂一样,微生物配体如肽聚糖,
CpG ODN和β-葡聚糖具有重编程巨噬细胞代谢和诱导记忆的能力
以线粒体生物发生为特征的表型,柠檬酸循环通量增加,Irg 1增加
表达和衣康酸盐产生,并伴随抗微生物功能的增强。
英文摘要
Project Summary
Hospital-acquired infections are a major threat to public health, impacting 2 million patients and causing at
least 90,000 deaths annually. Sepsis is a common complication in patients with hospital-acquired infections
and the leading cause of death in non-cardiac intensive care units (ICU). Attempts at treating hospital-acquired
infections and sepsis have proven exceedingly difficult and patients that survive sepsis suffer long-term
physical and cognitive disabilities and a high 1-year mortality rate. Therefore, new strategies are needed to
decrease the burden of hospital-acquired infections and sepsis. Immunotherapy aimed at inducing
innate immune memory provides a way of achieving that goal. Recent studies show that innate immune
cells can retain memory of prior pathogen exposure and are primed to elicit a robust, broad-spectrum
antimicrobial response to subsequent infection. Treatment with TLR4 ligands, such as monophosphoryl lipid A
(MPLA), confers innate immune memory and resistance to a broad array of clinically important pathogens that
persists for more than 2 weeks. We propose that the appropriate application of TLR4 ligand-based
immunotherapy to induce innate immune memory has significant potential to reduce the burden of
hospital-acquired infections and sepsis. Macrophages are the foundation for development of innate
immune memory. Recent evidence indicates that remodeling of macrophage metabolism is central to the
induction of innate immune memory. Priming with TLR4 ligands induces a macrophage metabolic phenotype
characterized by increased glycolysis, oxidative metabolism and mitochondrial biogenesis with increased citric
acid cycle flux and associated increases in immunoresponsive gene 1 (Irg1) expression and itaconate
production. We hypothesize that macrophage metabolic remodeling and the increased production of
Irg1 and itaconate are essential to generating innate immune memory. To define the underlying biology,
we will: (1). Determine how Irg1 and itaconate drive TLR4 agonist-induced innate immune memory in
macrophages; (2). Define the importance of Irg1, itaconate and Nrf2 as regulators of the host response to
infection with common hospital-acquired pathogens after TLR4 agonist treatment in vivo.; (3). Define the
intracellular signaling pathways driving mitochondrial biogenesis, Irg1 expression and itaconate production in
TLR4 agonist-primed macrophages; (4). Determine the ability of diverse microbial ligands to induce
macrophage mitochondrial biogenesis, reprogram mitochondrial metabolism and function and induce innate
immune memory. We will test the hypothesis that, like TLR4 agonists, microbial ligands such as peptidoglycan,
CpG ODN and β-glucan, have the ability to reprogram macrophage metabolism and induce a memory
phenotype characterized by mitochondrial biogenesis, increased citric acid cycle flux, increased Irg1
expression and itaconate production with associated enhancement of antimicrobial functions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Macrophage mitochodrial reprogramming and innate immune memory
-
批准号:10550138
-
项目类别:
-
资助金额:$42.5万
-
财政年份:2020
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Training Innate Immunity: A new approach to the treatment of Sepsis
-
批准号:10296894
-
项目类别:
-
资助金额:$55.35万
-
财政年份:2016
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Training Innate Immunity: A new approach to the treatment of Sepsis
-
批准号:10461115
-
项目类别:
-
资助金额:$52.84万
-
财政年份:2016
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Equipment supplement to "Training Innate Immunity: A new approach to the treatment of sepsis"
-
批准号:10794766
-
项目类别:
-
资助金额:$13.63万
-
财政年份:2016
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Equipment Supplement request for a BD LSR Fortessa Flow Cytometer
-
批准号:9275190
-
项目类别:
-
资助金额:$12.74万
-
财政年份:2016
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Training Innate Immunity: A new approach to the treatment of Sepsis
-
批准号:10669060
-
项目类别:
-
资助金额:$52.67万
-
财政年份:2016
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:7256520
-
项目类别:
-
资助金额:$25.06万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:7811704
-
项目类别:
-
资助金额:$12.53万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:8292209
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:8578744
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:8509831
-
项目类别:
-
资助金额:$38.18万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:9091565
-
项目类别:
-
资助金额:$39.11万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:8112517
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:7086177
-
项目类别:
-
资助金额:$25.8万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:8692836
-
项目类别:
-
资助金额:$38.86万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:8908015
-
项目类别:
-
资助金额:$27.54万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:6911533
-
项目类别:
-
资助金额:$26.43万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:6681426
-
项目类别:
-
资助金额:$26.17万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:6766014
-
项目类别:
-
资助金额:$26.43万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
Resistance of Beta 2 Microglobulin Null Mice to Sepsis
-
批准号:7786482
-
项目类别:
-
资助金额:$25.56万
-
财政年份:2003
-
负责人:EDWARD R SHERWOOD
-
依托单位:
海外基金